Research programme: cell-penetrating antibody therapeutics - LA Cell

Drug Profile

Research programme: cell-penetrating antibody therapeutics - LA Cell

Alternative Names: Intracellular Targeting Antibodies -LA Cell; iTAbs; KRASG12D iTAb; Mutant KRAS iTAb; STAT3 iTAb

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LA Cell
  • Developer City of Hope National Medical Center; LA Cell
  • Class Monoclonal antibodies
  • Mechanism of Action Protein modulators; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Mar 2017 Preclinical trials in Cancer in USA (IV)
  • 29 Sep 2015 LA Cell in-licenses a technology to develop cell-penetrating antibody therapeutics from City of Hope National Medical Center
  • 29 Sep 2015 Early research in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top